Leukemia

Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19, study results showed.

A vast majority of patients with acute myeloid leukemia and myelodysplastic syndrome converted to seropositivity after two COVID-19 vaccine doses, according to a study presented at ASH Annual Meeting and Exposition.

The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Considerable survival gaps exist among young white, Black and Hispanic individuals with acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Hispanic individuals appeared considerably underrepresented in a large clinical trial of adolescents and young adults with acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Goals-of-care discussions often occur too late for patients with poor-prognosis, high-risk acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

The FDA granted orphan drug designation to CT120, a novel chimeric antigen receptor T-cell therapy, for the treatment of B-cell acute lymphoblastic leukemia.

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

The addition of quizartinib to chemotherapy extended OS for certain adults with newly diagnosed acute myeloid leukemia, according to topline data released by the agent’s manufacturer.